

CITATION REPORT

List of articles citing

FDA and EMA Approvals of New Breast Cancer Drugs-A Comparative Regulatory Analysis

DOI: 10.3390/cancers12020437
Cancers, 2020, 12, .

Source: <https://exaly.com/paper-pdf/77234456/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|----|---|-----|-----------|
| 15 | Nursing Personnel in the Era of Personalized Healthcare in Clinical Practice. <i>Journal of Personalized Medicine</i> , 2020 , 10, | 3.6 | 4 |
| 14 | Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial. <i>Cancers</i> , 2020 , 12, | 6.6 | 2 |
| 13 | Epigenetics in Breast Cancer Therapy-New Strategies and Future Nanomedicine Perspectives. <i>Cancers</i> , 2020 , 12, | 6.6 | 17 |
| 12 | New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?pi. <i>Cancers</i> , 2020 , 12, | 6.6 | 15 |
| 11 | Use of artificial cells as drug carriers. <i>Materials Chemistry Frontiers</i> , 2021 , 5, 6672-6692 | 7.8 | 1 |
| 10 | Designing and Immunomodulating Multiresponsive Nanomaterial for Cancer Theranostics. <i>Frontiers in Chemistry</i> , 2020 , 8, 631351 | 5 | 4 |
| 9 | Clinical trials in drug delivery for the treatment of cancer. 2021 , 509-519 | | 1 |
| 8 | Current Perspectives on Taxanes: Focus on Their Bioactivity, Delivery and Combination Therapy. <i>Plants</i> , 2021 , 10, | 4.5 | 17 |
| 7 | Accelerating regulatory approval of anticancer therapies: Benefits, drawbacks and recommendations for a more sustainable approach.. <i>Journal of Cancer Policy</i> , 2021 , 29, 100296 | 1 | 0 |
| 6 | Computationally repurposing drugs for breast cancer subtypes using a network-based approach.. <i>BMC Bioinformatics</i> , 2022 , 23, 143 | 3.6 | 1 |
| 5 | A detailed analysis of expedited regulatory review time of marketing authorization applications for new anticancer drugs in the US and EU.. <i>Clinical and Translational Science</i> , 2022 , | 4.9 | 0 |
| 4 | HER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment. <i>Cancers</i> , 2022 , 14, 2424 | 6.6 | 0 |
| 3 | Development of a Validated UPLC ^{MS} /MS Method for Simultaneous Estimation of Neratinib and Curcumin in Human Plasma: Application to Greenness Assessment and Routine Quantification. | | 1 |
| 2 | State of art in the chemistry of nucleoside-based Pt(II) complexes. 2023 , 131, 106325 | | 0 |
| 1 | Trends in endpoint use in pivotal trials and efficacy for US Food and Drug Administration-approved solid tumor therapies, 1995-2021. 2022 , 28, 1219-1223 | | 0 |